Home LiteratureArticle Details
PMID: 2757899 Published · ppublish English Clinical Trial Journal Article Randomized Controlled Trial

Pharmacokinetics of intravenous cilazaprilat in normal volunteers.

British journal of clinical pharmacology ·Vol. 27 ·No. 6 ·1989-06-00 ·Pages 873-5

Whitehead EM, Walters GE, Williams PE, Johnston GD

Abstract

The pharmacokinetics of 1 mg, 2 mg and 4 mg of cilazaprilat administered intravenously were determined in a group of eight volunteers. The fall in plasma concentration was polyphasic. Elimination was predominantly by renal excretion of the unchanged drug. The mean renal clearance values following 1 mg, 2 mg and 4 mg doses were 5.3 +/- 0.5, 8.1 +/- 0.5, and 9.8 +/- 0.5 l h-1 and plasma clearances were 7.8 +/- 0.5, 10.4 +/- 0.5 and 11.8 +/- 0.6 l h-1, respectively. Thus, plasma and renal clearances were dose dependent. ACE inhibition was greater than 82% for the first 4 h and about 55% at 24 h, after all three doses. There were no significant haemodynamic effects at any dose.

MeSH Terms
Adult Angiotensin-Converting Enzyme Inhibitors/administration & dosage,pharmacokinetics,pharmacology Cilazapril/analogs & derivatives Hemodynamics/drug effects Humans Infusions, Intravenous Male Pyridazines/administration & dosage,pharmacokinetics,pharmacology Regional Blood Flow/drug effects
Chemicals
Angiotensin-Converting Enzyme Inhibitors Pyridazines Cilazapril cilazaprilat
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Whitehead E M
Department of Therapeutics and Pharmacology, Queen's University, Belfast, Northern Ireland.
Walters G E
Williams P E
Johnston G D
References (6)
6 references, click to expand
  1. Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers.
    J Cardiovasc Pharmacol. 1987 Jan;9(1):26-31 PMID: 2434790
  2. Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model.
    J Cardiovasc Pharmacol. 1987 Jan;9(1):32-8 PMID: 2434791
  3. Biological properties of the angiotensin-converting enzyme inhibitor cilazapril.
    J Cardiovasc Pharmacol. 1985 May-Jun;7(3):569-80 PMID: 2410692
  4. Captopril kinetics.
    Clin Pharmacol Ther. 1982 Apr;31(4):452-8 PMID: 7037265
  5. Enalapril maleate and a lysine analogue (MK-521): disposition in man.
    Br J Clin Pharmacol. 1982 Sep;14(3):357-62 PMID: 6289858
  6. Disposition of fosinopril sodium in healthy subjects.
    Br J Clin Pharmacol. 1988 Jan;25(1):9-15 PMID: 2967089
Article Info
Journal
British journal of clinical pharmacology
Abbr.
Br J Clin Pharmacol
ISSN
0306-5251
Published
1989-06-00
Pages
873-5
Language
English
Region
England
NLM ID
7503323
PMCID
PMC1379818
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com